Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-Derived VSTs for Viral Infections After Stem Cell Transplant
NCT02048332Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Feb 2014
- Primary completion
- Jan 2027
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of viral-specific T-cells in viral infection, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Successful production of viral specific T-cells at 30 days, Percentage of patients who do not have infusional toxicity at 30 minutes and 1 more. Started Feb 2014; status: recruiting.
02
Drugs
viral-specific T-cells
03
Conditions
viral infection
Beyond the preview
Go deeper on NCT02048332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048332.